| Name | Title | Contact Details |
|---|---|---|
Rachel McMinn |
President and Chief Executive Officer | Profile |
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
Cellestis Limited is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
febit is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.